Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

Appeal

Appeal letter - Neuroendocrine Cancer UK : Appeal letter (MSWord 88 KB)

Scrutiny letter to Neuroendocrine Cancer UK : Scrutiny letter (MSWord 40 KB)

Response to scrutiny letter - Neuroendocrine Cancer UK : Response to scrutiny letter (MSWord 77 KB)

NICE's final response to Neuroendocrine Cancer UK : NICE's final response (MSWord 57 KB)

Appeal letter - Ipsen : Appeal letter (MSWord 195 KB)

Scrutiny letter to Ipsen : Scrutiny letter (MSWord 64 KB)

Response to scrutiny letter - Ipsen : Response to scrutiny letter (MSWord 95 KB)

Response to scrutiny letter - Ipsen Clinician Validation Report : Response to scrutiny letter (MSWord 46 KB)

Final draft guidance

Final draft guidance (PDF 222 KB)

Public committee slides (PDF 838 KB)

Committee papers (PDF 1.48 MB)

Draft guidance

Draft guidance (downloadable version) (PDF 246 KB)

Committee papers (PDF 8.85 MB)

Public committee slides (PowerPoint 1.97 MB)

Equality impact assessment (downloadable version) (PDF 127 KB)

Committee meeting

Final scope (PDF 124 KB)

Final stakeholder list (PDF 154 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 211 KB)

Draft scope post referral (PDF 178 KB)